BAUSCH HEALTH CANADA ANNOUNCES EXPANDED PUBLIC REIMBURSEMENT FOR (PR)OKEDI® (RISPERIDONE FOR EXTENDED-RELEASE INJECTABLE SUSPENSION) ACROSS CANADA FOR THE TREATMENT OF SCHIZOPHRENIA

Reuters · 3d ago

Please log in to view news